๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Antibodies against serotonin and gangliosides in patients with fibromyalgia and major depression

โœ Scribed by W. Samborski; A. Sluzewska; J. K. Lacki; M. Sobieska; R. Klein; S. Mackiewicz


Publisher
John Wiley and Sons
Year
1998
Tongue
English
Weight
75 KB
Volume
13
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

โœฆ Synopsis


Antibodies against serotonin and gangliosides in patients with ยฎbromyalgia and major depression

The ยฎbromyalgia syndrome (FMS) is a nonarticular disorder associated with disturbances in serotonin (5-HT) metabolism Samborski et al., 1996a,b). Moreover the psychological proยฎles of these patients revealed elevated scores for depression and current or past psychiatric disturbances had been reported for up to 72 per cent of patients . Major depression (MD) is associated with low 5-HT concentration and with changes in immune reactivity. In this study we were interested in looking for the occurrence of autoimmune reactions against serotonin and related structures in ยฎbromyalgia and major depression. Twenty-six ยฎbromyalgia patients and 20 patients with major depression were included in the study. The control group consisted of 25 healthy individuals. None of the patients suered from any speciยฎc rheumatic disease or other disease associated with muscle pain. Blood samples were obtained at 7.30 am, centrifuged and the serum frozen at ร€808C until analysis. A standard ELISA


๐Ÿ“œ SIMILAR VOLUMES


Serotonin antibodies in relation to immu
โœ A. Sluzewska; W. Samborski; M. Sobieska; R. Klein; E. Bosmans; J. K. Rybakowski ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 126 KB ๐Ÿ‘ 2 views

Serum antibodies against serotonin and gangliosides, the serum concentration of serotonin in addition to indicators of immune activation, such as acute phase proteins (apps) and interleukin-6 (IL-6), were investigated in 20 major depressed patients and 32 normal controls. Antibody-positive sera agai

Comparison of pramipexole, fluoxetine, a
โœ Mark H. Corrigan; Angelita Q. Denahan; C. Eugene Wright; Rhonda J. Ragual; Dwigh ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 195 KB ๐Ÿ‘ 2 views

Pramipexole, a dopamine D 2 receptor agonist, was tested in 174 patients with major depression, with or without melancholia and without psychotic features. Three daily dose levels (0.375 mg, 1.0 mg, and 5.0 mg) were compared to fluoxetine (Prozac) at 20 mg and placebo in a randomized, double-blind,